Targets › GSN
2 programs from 1 company in 2 trials: 2 Phase 2; Infectious disease, Other; next expected readout Oct 2027.
Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed. (UniProt, P06396)
Open in Phaseline: the race on GSN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BioAegis Therapeutics | Rhu-pGSN Recombinant human gelsolin - actin-scavenging protein that reduces inflammatory cell damag | GSN | Phase 2 | Acute Respiratory Distress Syndrome | Oct 2027 |
| BioAegis Therapeutics | Recombinant human plasma gelsolin Plasma gelsolin acts as a scavenger of actin released from damaged cells and modulates inf | GSN | Phase 2 | Decompression Sickness | – |
Acute Respiratory Distress Syndrome (1) Decompression Sickness (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.